BioPharma Dive July 16, 2024
The Merck KGaA spinout has a tau-regulating medicine it claims could be an “ideal therapy” for Alzheimer’s patients. The pitch has intrigued both healthcare investors and big pharmas’ venture arms.
Asceneuron, a Switzerland-based biotechnology company, has raised another $100 million to support its work developing drugs that target a protein linked to Alzheimer’s disease and other nerve-destroying disorders.
Disclosed Tuesday, the Series C fundraising round received more interest than Asceneuron initially expected. The holding company behind Novo Nordisk led the round. Healthcare investors EQT Life Sciences, OrbiMed, SR One, Sofinnova Partners and GSK Equity Investments also participated, as did the venture arms of Johnson & Johnson and Merck KGaA.
Asceneuron plans to use the money to push its most advanced...
Today's Sponsors
Today's Sponsor